Journal article
New antithrombotic agents
Abstract
The development of new antithrombotic agents has been stimulated by clinical needs and by advances in biotechnology that have made it possible to produce drugs that target specific steps in thrombogenesis. Heparin has pharmacokinetic and biophysical limitations that are overcome by new anticoagulants. Of these, low-molecular-weight heparin and direct inhibitors of thrombin have been evaluated clinically. Coumarins require careful laboratory …
Authors
Hirsh J; Weitz JI
Journal
The Lancet, Vol. 353, No. 9162, pp. 1431–1436
Publisher
Elsevier
Publication Date
4 1999
DOI
10.1016/s0140-6736(98)09233-2
ISSN
0140-6736